comprehensive -WSS

comprehensive

author：explore 2025-10-01 01:49:57 - browse：716

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： When women are denied an abortion, their children fare worse than peers

explore

WSS

Search warrant issued in 1996 disappearance of Kristin Smart

Bristol 'take

Phenylephrine and the overlooked value of the placebo effect

The future of health care in the House

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA authorizes Novavax’s updated Covid

leisure time

comprehensive

focus

How to save PrEP access — and even expand it

Was Amgen transparent enough on FDA's concern on cancer drug?

Psychedelics group wrestles with new pharma identity

VC firm General Catalyst wants to buy a health system

Trump demands the U.S. pay no more for drugs than other countries … again

Was Amgen transparent enough on FDA's concern on cancer drug?

Malaria cases in Florida and Texas: Here’s what you need to know

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

The high cost of giving birth even with insurance

Pope Francis asks Church to identify 21st

entertainment

Bill would stop addiction treatment from triggering child abuse inquiry

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Was Amgen transparent enough on FDA's concern on cancer drug?

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Condition critical? Britain's beloved but battered National Health Service turns 75

explore

focus

hotspot

knowledge